Apollomics announces top-line results for phase 3 bridging trial of uproleselan in china in patients with relapsed or refractory acute myeloid leukemia

Foster city, calif., dec. 20, 2024 (globe newswire) -- apollomics inc. (nasdaq: aplm) (“apollomics” or the “company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its phase 3 bridging trial of uproleselan in china in patients with relapsed or refractory acute myeloid leukemia. the trial did not demonstrate favorable benefit for uproleselan.
APLM Ratings Summary
APLM Quant Ranking